340 B Program Recertification

In May 2013, all Title X Family Planning Grantees participating in the 340B Program will be required to complete the annual re-certification into the program. In the past, this has been completed for all agencies by the state RH program office, but going forward it will have to be done by the individual delegate agency. Please see the attached flyer about an upcoming webinar providing information about the process. Don’t worry if you are unable to attend the webinar; information will be forthcoming from the RH program office in the near future. If you have any questions, please contact Karol Almroth (971) 673-0357.

New Birth Control Consent Forms Available

We are very excited to announce the arrival of sample birth control consent forms. The sample forms total 20 in all and are now available on our website. Included in the sample forms are consents in English and Spanish for all prescriptive methods of birth control as well as a single consent form in English and Spanish that covers all hormonal contraceptive methods. Remember that both Title X and CCare require that clients sign a method specific consent form prior to receiving the method and also that certain elements are included in the consent. All of the sample consent forms now available contain the required Title X elements.

Please visit our website to download and edit the forms for your use. The forms are located on the Materials for All Reproductive Health Providers page below under “Tools and Resources.”

http://public.health.oregon.gov/HealthyPeopleFamilies/ReproductiveSexualHealth/Resources/Pages/AllProvidersMaterials.aspx

Feel free to alter the samples, just keep in mind that each heading must be addressed to remain Title X compliant. A big thanks to Linn County for allowing us to use their template!
Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors

The American Society for Colposcopy and Cervical Pathology (ASCCP) has just updated their "Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors" as well as Algorithms for management. Since these are considered a "National Standard of Care" that many clinics are using in protocols, please share this information with clinical staff.

These Guidelines and Algorithms are available at:


Recent Press Coverage Linking Azithromycin to Increased Risk of Sudden Death - Article from the CDC

Several media outlets have reported on a study that links azithromycin to sudden death. Azithromycin is a commonly used antibiotic, often prescribed to treat respiratory infections, ear infections, and sexually transmitted diseases (STDs).

As the public health agency tasked with researching and developing STD treatment guidelines, we want to take this opportunity to point out that the findings from this study may not necessarily apply to patients who are treated with azithromycin for chlamydia or gonorrhea. It is important to note that a five day regimen of azithromycin was studied and discussed in recent media reports -- not a single dose regimen as recommended for chlamydia or dual therapy for gonorrhea. For additional information about Azithromycin from the U.S. Food and Drug Administration, please visit http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm

(Continued on next page)
Do not modify treatment regimens for patients receiving azithromycin for chlamydia and gonorrhea. CDC’s guidance for treating chlamydia and gonorrhea with azithromycin remain as follows:

**Recommended Regimens for Treating Chlamydial Infections**
Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice a day for 7 days

**Recommended Regimens for Treating Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum**
Recommended regimen: Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1g orally in a single dose OR Doxycycline 100 mg orally twice a day for 7 days*

Alternative regimen: If ceftriaxone is not available: Cefixime 400 mg in a single oral dose PLUS Azithromycin 1 g orally in a single dose OR Doxycycline 100 mg orally twice daily for 7 days* PLUS Test-of-cure in 1 week

* Because of the high prevalence of tetracycline resistance among Gonococcal Isolate Surveillance Project isolates, particularly those with elevated minimum inhibitory concentrations to cefixime, the use of azithromycin as the second antimicrobial is preferred.


If you have questions or concerns, please contact 1-800-CDC-INFO.

Source: [http://www.cdc.gov/std/treatment/azithromycin.htm](http://www.cdc.gov/std/treatment/azithromycin.htm)
California Family Health Council Learning Exchange Trainings

Providing Patient-Centered Education about Safe and Healthy Anal Sex

Date: April 4, 2013  Time: 12:00 pm - 1:00 pm  Fee: $60.00

This webinar will review messages you can provide your patients on the potentially difficult-to-discuss topic of safe anal sex practices. A review of the relevant anatomical structures will be included. We also will be examining attitudes and beliefs that are important to present in order to provide unbiased, non-judgmental patient-centered information about anal sex.

- Identify the structures of the anus and rectum
- List 5 things your patient can do to keep anal sex safe and healthy
- Identify how best to provide unbiased information about anal sex

Register today!

Providing Patient-Centered Contraceptive Counseling

Date: April 9, 2013  Time: 12:00 pm - 1:00 pm  Fee: $60.00

This webinar will provide participants with a basic framework to use when conducting a patient-centered contraceptive counseling session. The webinar will also review important communication skills to encourage your patients’ active participation in identifying a contraceptive method that is best for them. Examples of questions to ask and language to use will be provided to enhance your patient-centered contraceptive counseling sessions. Learning Objectives:

- Describe communication techniques which can help encourage your patients to select a contraceptive method that is best for them
- Explain the basic framework for conducting an effective patient-centered contraceptive counseling session
- Identify two essential questions to ask during a patient-centered contraceptive counseling session

Register today!
Reproductive Health Program Staff Contact List

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Email</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judy Andreasen</td>
<td>Administrative Support</td>
<td><a href="mailto:judith.andreasen@state.or.us">judith.andreasen@state.or.us</a></td>
<td>971-673-0355</td>
</tr>
<tr>
<td>Elizabeth Gharst</td>
<td>Administrative Support</td>
<td><a href="mailto:elizabeth.a.gharst@state.or.us">elizabeth.a.gharst@state.or.us</a></td>
<td>971-673-0363</td>
</tr>
<tr>
<td>Helene Rimberg</td>
<td>Manager</td>
<td><a href="mailto:helene.m.rimberg@state.or.us">helene.m.rimberg@state.or.us</a></td>
<td>971-673-0364</td>
</tr>
<tr>
<td>Karol Almroth</td>
<td>Operations Coordinator</td>
<td><a href="mailto:karol.l.almroth@state.or.us">karol.l.almroth@state.or.us</a></td>
<td>971-673-0357</td>
</tr>
<tr>
<td>Alison Babich</td>
<td>Fiscal Analyst</td>
<td><a href="mailto:alison.a.babich@state.or.us">alison.a.babich@state.or.us</a></td>
<td>971-673-0356</td>
</tr>
<tr>
<td>Marsha Brantley</td>
<td>Health Education Consultant</td>
<td><a href="mailto:marsha.c.brantley@state.or.us">marsha.c.brantley@state.or.us</a></td>
<td>971-673-0359</td>
</tr>
<tr>
<td>Connie Clark</td>
<td>Nurse Consultant</td>
<td><a href="mailto:connie.r.clark@state.or.us">connie.r.clark@state.or.us</a></td>
<td>541-386-3199 x200</td>
</tr>
<tr>
<td>Carol Elliott</td>
<td>Nurse Consultant</td>
<td><a href="mailto:carol.j.elliott@state.or.us">carol.j.elliott@state.or.us</a></td>
<td>971-673-0362</td>
</tr>
<tr>
<td>Emily Elman</td>
<td>Policy &amp; Research Analyst</td>
<td><a href="mailto:emily.l.elman@state.or.us">emily.l.elman@state.or.us</a></td>
<td>971-673-0219</td>
</tr>
<tr>
<td>Erin Hardman</td>
<td>Fiscal Coordinator</td>
<td><a href="mailto:erin.l.hardman@state.or.us">erin.l.hardman@state.or.us</a></td>
<td>971-673-0367</td>
</tr>
<tr>
<td>Rachel Linz</td>
<td>Research Analyst</td>
<td><a href="mailto:rachel.s.linz@state.or.us">rachel.s.linz@state.or.us</a></td>
<td>971-673-0358</td>
</tr>
<tr>
<td>Lesli Uebel</td>
<td>Quality Improvement Coordinator</td>
<td><a href="mailto:lesli.l.uebel@state.or.us">lesli.l.uebel@state.or.us</a></td>
<td>541-757-5155</td>
</tr>
<tr>
<td>Pi Winslow</td>
<td>CCare training, eligibility screening, billing policies, provider enrollment</td>
<td><a href="mailto:pi.v.winslow@state.or.us">pi.v.winslow@state.or.us</a></td>
<td>971-673-0227</td>
</tr>
</tbody>
</table>